Research progress of tumor immunomodulation strategies based on nanodrug delivery system

LIU Yanhong; CHEN Liqing; ZHANG Xintong; GAO Zhonghao; HUANG Wei

doi:10.11665/j.issn.1000-5048.2023021501

Journal of China Pharmaceutical University > 2023 > 54(1): 5-14. > DOI: 10.11665/j.issn.1000-5048.2023021501

LIU Yanhong, CHEN Liqing, ZHANG Xintong, GAO Zhonghao, HUANG Wei. Research progress of tumor immunomodulation strategies based on nanodrug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 5-14. DOI: 10.11665/j.issn.1000-5048.2023021501

Citation:

PDF (2699 KB)

Research progress of tumor immunomodulation strategies based on nanodrug delivery system

Beijing Municipal Key Laboratory of Drug Delivery Technology and Novel Formulations, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050, China

More Information

Received Date: February 14, 2023
Revised Date: March 06, 2023

Graphical Abstract

Abstract

Abstract

Tumor immunotherapy is a therapeutic modality that uses immunological principles and methods to activate and enhance the body''s immune system to generate immune response for the removal of tumour cells. Many new immunotherapeutic agents have demonstrated effective anti-tumour capabilities, yet their clinical use is challenging due to the complex mechanisms of tumour immune escape. Meanwhile, these drugs would accumulate in different tissues and organs in the human body and be unable to achieve precise and specific targeting therapeutic effects, resulting in serious immune-related adverse effects, which greatly hinders the clinical potential of immunotherapy.Nanodrug delivery systems can deliver immunotherapeutic drugs to target tissues or specific immune cells precisely, thereby enhancing immune effects and reducing side effects.This paper reviews the research progress of nanodrug delivery systems in tumour immunotherapy in recent years based on the regulatory mechanism of the anti-tumour immune response, with a prospect of the challenges and development in this field.
- tumour immunotherapy,
- nanodrug delivery systems,
- tumour immune microenvironment

FullText(HTML)

References (50)

References

[1]	. J Exp Clin Cancer Res，2019，38（1）：268.
[2]	Chen DS，Mellman I. Oncology meets immunology：the cancer-immunity cycle［J］. Immunity，2013，39（1）：1-10.
[3]	Li QQ，Shi ZQ，Zhang F，et al. Symphony of nanomaterials and immunotherapy based on the cancer-immunity cycle［J］. Acta Pharm Sin B，2022，12（1）：107-134.
[4]	Starzer AM，Preusser M，Berghoff AS. Immune escape mechanisms and therapeutic approaches in cancer：the cancer-immunity cycle［J］. Ther Adv Med Oncol，2022，14：17588359221096219.
[5]	Schlake T，Thess A，Thran M，et al. mRNA as novel technology for passive immunotherapy［J］. Cell Mol Life Sci，2019，76（2）：301-328.
[6]	Ma S，Li XC，Wang XY，et al. Current progress in CAR-T cell therapy for solid tumors［J］. Int J Biol Sci，2019，15（12）：2548-2560.
[7]	Chen LP，Han X. Anti-PD-1/PD-L1 therapy of human cancer：past，present，and future［J］. J Clin Invest，2015，125（9）：3384-3391.
[8]	Saxena M，van der Burg SH，Melief CJM，et al. Therapeutic cancer vaccines［J］. Nat Rev Cancer，2021，21（6）：360-378.
[9]	Yu MH，Yang W，Yue WW，et al. Targeted cancer immunotherapy：nanoformulation engineering and clinical translation［J］. Adv Sci （Weinh），2022，9（35）：e2204335.
[10]	Liu ZG，Jiang W，Nam J，et al. Immunomodulating nanomedicine for cancer therapy［J］. Nano Lett，2018，18（11）：6655-6659.
[11]	Francis MJ. Recent advances in vaccine technologies［J］. Vet Clin North Am Small Anim Pract，2018，48（2）：231-241.
[12]	Davodabadi F，Sarhadi M，Arabpour J，et al. Breast cancer vaccines：new insights into immunomodulatory and nano-therapeutic approaches［J］. J Control Release，2022，349：844-875.
[13]	Mi Y，4th Hagan CT，Vincent BG，et al. Emerging nano-/ microapproaches for cancer immunotherapy［J］. Adv Sci （Weinh），2019，6（6）：1801847.
[14]	Chen J，Fang HP，Hu YY，et al. Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy［J］. Bioact Mater，2022，7：167-180.
[15]	Zhou L，Hou B，Wang DG，et al. Engineering polymeric prodrug nanoplatform for vaccination immunotherapy of cancer［J］. Nano Lett，2020，20（6）：4393-4402.
[16]	Yang R，Xu J，Xu LG，et al. Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination［J］. ACS Nano，2018，12（6）：5121-5129.
[17]	Lim JP，Gleeson PA. Macropinocytosis：an endocytic pathway for internalising large gulps［J］. Immunol Cell Biol，2011，89（8）：836-843.
[18]	Yang C，Zhang F，Chen FM，et al. Biomimetic nanovaccines potentiating dendritic cell internalization via CXCR4-mediated macropinocytosis［J］. Adv Healthc Mater，2023，12（5）：e2202064.
[19]	Guo JF，Zou YF，Huang L. Nano delivery of chemotherapeutic ICD inducers for tumor immunotherapy［J］. Small Methods，2023：e2201307.
[20]	Li YH，Liu XH，Zhang X，et al. Immunogenic cell death inducers for enhanced cancer immunotherapy［J］. Chem Commun，2021，57（91）：12087-12097.
[21]	Banstola A，Poudel K，Kim JO，et al. Recent progress in stimuli-responsive nanosystems for inducing immunogenic cell death［J］. J Control Release，2021，337：505-520.
[22]	Zhou JY，Wang GY，Chen YZ，et al. Immunogenic cell death in cancer therapy：present and emerging inducers［J］. J Cell Mol Med，2019，23（8）：4854-4865.
[23]	Song L，Hao Y，Wang CJ，et al. Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer［J］. J Control Release，2022，350：922-932.
[24]	Qiu XY，Qu Y，Guo BB，et al. Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer［J］. J Control Release，2022，341：498-510.
[25]	Liang RJ，Liu LL，He HM，et al. Oxygen-boosted immunogenic photodynamic therapy with gold nanocages@manganese dioxide to inhibit tumor growth and metastases［J］. Biomaterials，2018，177：149-160.
[26]	Li W，Yang J，Luo LH，et al. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death［J］. Nat Commun，2019，10（1）：3349.
[27]	Emens LA，Silverstein SC，Khleif S，et al. Toward integrative cancer immunotherapy：targeting the tumor microenvironment［J］. J Transl Med，2012，10：70.
[28]	Cao J，Yan Q. Cancer epigenetics，tumor immunity，and immunotherapy［J］. Trends Cancer，2020，6（7）：580-592.
[29]	Xiang XN，Wang JG，Lu D，et al. Targeting tumor-associated macrophages to synergize tumor immunotherapy［J］. Signal Transduct Target Ther，2021，6（1）：75.
[30]	Han SL，Wang WJ，Wang SF，et al. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes［J］. Theranostics，2021，11（6）：2892-2916.
[31]	Liaw K，Reddy R，Sharma A，et al. Targeted systemic dendrimer delivery of CSF-1R inhibitor to tumor-associated macrophages improves outcomes in orthotopic glioblastoma［J］. Bioeng Transl Med，2021，6（2）：e10205.
[32]	Zhao Y，Rahmy S，Liu ZM，et al. Rational targeting of immunosuppressive neutrophils in cancer［J］. Pharmacol Ther，2020，212：107556.
[33]	Zhang YT，Guoqiang L，Sun MM，et al. Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment［J］. Cancer Biol Med，2020，17（1）：32-43.
[34]	Que HY，Fu QM，Lan TX，et al. Tumor-associated neutrophils and neutrophil-targeted cancer therapies［J］. Biochim Biophys Acta Rev Cancer，2022，1877（5）：188762.
[35]	Tang LG，Wang ZT，Mu QC，et al. Targeting neutrophils for enhanced cancer theranostics［J］. Adv Mater，2020，32（33）：e2002739.
[36]	Mao XQ，Xu J，Wang W，et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment：new findings and future perspectives［J］. Mol Cancer，2021，20（1）：131.
[37]	Panagi M，Mpekris F，Chen PW，et al. Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models［J］. Nat Commun，2022，13（1）：7165.
[38]	Tan YN，Huang JD，Li YP，et al. Near-infrared responsive membrane nanovesicles amplify homologous targeting delivery of anti-PD immunotherapy against metastatic tumors［J］. Adv Healthc Mater，2022，11（6）：e2101496.
[39]	Tang XY，Luo ZL，Xiong YL，et al. The proliferative role of immune checkpoints in tumors：double regulation［J］. Cancers，2022，14（21）：5374.
[40]	Archilla-Ortega A，Domuro C，Martin-Liberal J，et al. Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity［J］. J Exp Clin Cancer Res，2022，41（1）：62.
[41]	Yang L，Pang YL，Moses HL. TGF-β and immune cells：an important regulatory axis in the tumor microenvironment and progression［J］. Trends Immunol，2010，31（6）：220-227.
[42]	Liu M，Wang X，Wang L，et al. Targeting the IDO1 pathway in cancer：from bench to bedside［J］. J Hematol Oncol，2018，11（1）：100.
[43]	Haist M，Mail?nder V，Bros M. Nanodrugs targeting T cells in tumor therapy［J］. Front Immunol，2022，13：912594.
[44]	Xue S，Hu M，Iyer V，et al. Blocking the PD-1/PD-L1 pathway in glioma：a potential new treatment strategy［J］. J Hematol Oncol，2017，10（1）：81.
[45]	Gao Y，Ouyang ZJ，Yang C，et al. Overcoming T cell exhaustion via immune checkpoint modulation with a dendrimer-based hybrid nano complex［J］. Adv Healthc Mater，2021，10（19）：e2100833.
[46]	Yang GX，Zhou D，Dai Y，et al. Construction of PEI-EGFR-PD-L1-siRNA dual functional nano-vaccine and therapeutic efficacy evaluation for lung cancer［J］. Thorac Cancer，2022，13（21）：2941-2950.
[47]	Huo JL，Wang YT，Fu WJ，et al. The promising immune checkpoint LAG-3 in cancer immunotherapy：from basic research to clinical application［J］. Front Immunol，2022，13：956090.
[48]	Wan WJ，Huang G，Wang Y，et al. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy［J］. Acta Biomater，2021，136：473-484.
[49]	Selvan SR，Dowling JP，Kelly WK，et al. Indoleamine 2，3-dioxygenase （IDO）：biology and target in cancer immunotherapies［J］. Curr Cancer Drug Targets，2016，16（9）：755-764.
[50]	Mei KC，Liao YP，Jiang JH，et al. Liposomal delivery of mitoxantrone and a cholesteryl indoximod prodrug provides effective chemo-immunotherapy in multiple solid tumors［J］. ACS Nano，2020，14（10）：13343-13366.

Cited By

Cited by

Periodical cited type(2)

1.	陈哲铭，葛婧雯，陈延玮，张政，赵双双，赵峰，陈宝定. 纳米材料介导焦亡促进抗肿瘤免疫治疗的作用机制及研究进展. 江苏大学学报(医学版). 2024(04): 290-296 .
2.	戴婷，陈萍，李帅，路蕾，周翔，欧阳永长. 基于OBE理念的基因工程载体情境教学探索. 科技风. 2024(30): 103-105 .

Other cited types(1)

Get Citation

PDF

XML

Article views (1389) PDF downloads (1085) Cited by(3)

Turn off MathJax

Article Contents

Abstract

References

Research progress of tumor immunomodulation strategies based on nanodrug delivery system

Abstract

References

Cited by

Periodical cited type(2)

Other cited types(1)

Catalog

Export File

Citation

Format

Content